Navelbine Base: Full Drug Profile
Navelbine Base - General Information
Navelbine Base (Navelbine®) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. [Wikipedia]
Pharmacology of Navelbine Base
Navelbine Base is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Navelbine Base binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Navelbine Base has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Navelbine Base for patients
Navelbine Base Interactions
Acute pulmonary reactions have been reported with NAVELBINE and other anticancer vinca alkaloids used in conjunction with mitomycin. Although the pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin, the incidence of granulocytopenia with NAVELBINE used in combination with cisplatin is significantly higher than with single-agent NAVELBINE. Patients who receive NAVELBINE and paclitaxel, either concomitantly or sequentially, should be monitored for signs and symptoms of neuropathy. Administration of NAVELBINE to patients with prior or concomitant radiation therapy may result in radiosensitizing effects.
Caution should be exercised in patients concurrently taking drugs known to inhibit drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily, or in patients with hepatic dysfunction. Concurrent administration of vinorelbine tartrate with an inhibitor of this metabolic pathway may cause an earlier onset and/or an increased severity of side effects.
Navelbine Base Contraindications
Administration of NAVELBINE is contraindicated in patients with pretreatment granulocyte counts <1,000 cells/mm3.
Additional information about Navelbine Base
Navelbine Base Indication: For the treatment of non-small-cell lung carcinoma Mechanism Of Action: The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Vinorelbine Synonyms: Vinorelbin; Vinorelbina [Spanish]; Vinorelbine Bitartrate; Vinorelbine Ditartarate; Vinorelbine Ditartrate; Vinorelbine Tartrate; Vinorelbinum [Latin] Drug Category: Radiation-Sensitizing Agents; Antineoplastic Agents Drug Type: Small Molecule; Approved; Investigational Other Brand Names containing Vinorelbine: Navelbine; Navelbine Base; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: ~27% Biotransformation: Not Available Half Life: 27.7-43.6 hours Dosage Forms of Navelbine Base: Solution Intravenous Chemical IUPAC Name: Not Available Chemical Formula: C45H54N4O8 Vinorelbine on Wikipedia: https://en.wikipedia.org/wiki/Vinorelbine Organisms Affected: Humans and other mammals